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Type 2C and 2D limb girdle muscular dystrophies (LGMD) are a group of autosomal reces-
sive limb girdle muscular dystrophies manifested by proximal myopathy, impaired respira-
tory muscle function and cardiomyopathy. The correlation and the prognostic impact of
respiratory and heart impairment are poorly described. We aimed to describe the long-term
cardiac and respiratory follow-up of these patients and to determine predictive factors of
cardio-respiratory events and mortality in LGMD 2C and 2D.
Methods
We reviewed the charts of 34 LGMD patients, followed from 2005 to 2015, to obtain echo-
cardiographic, respiratory function and sleep recording data. We considered respiratory
events (acute respiratory failure, pulmonary sepsis, atelectasis or pneumothorax), cardiac
events (acute heart failure, significant cardiac arrhythmia or conduction block, ischemic
stroke) and mortality as outcomes of interest for the present analysis.
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Results
A total of 21 patients had type 2C LGMD and 13 patients had type 2D. Median age was 30
years [IQR 24–38]. At baseline, median pulmonary vital capacity (VC) was 31% of predicted
value [20–40]. Median maximal inspiratory pressure (MIP) was 31 cmH2O [IQR 20.25–
39.75]. Median maximal expiratory pressure (MEP) was 30 cm H2O [20–36]. Median left
ventricular ejection fraction (LVEF) was 55% [45–64] with 38% of patients with LVEF <50%.
Over a median follow-up of 6 years, we observed 38% respiratory events, 14% cardiac
events and 20%mortality. Among baseline characteristics, LVEF and left ventricular end
diastolic diameter (LVEDD) were associated with mortality, whilst respiratory parameters
(VC, MIP, MEP) and the need for home mechanical ventilation (HMV) were associated with
respiratory events.
Conclusion
In our cohort of severely respiratory impaired type 2C and 2D LGMD, respiratory morbidity





Type 2C and 2D limb girdle muscular dystrophies (LGMD) are autosomal recessive muscular
dystrophies that belong to the group of sarcoglycanopathies (SG). They are characterized by
mutations in the genes encoding sarcoglycans. Mutations in gamma-sarcoglycan (SGCC gene)
[1] and alpha-sarcoglycan (SGCA gene) [2] are responsible for LGMD 2C and LGMD 2D
respectively. Sarcoglycans belong to a group of proteins associated with dystrophin (dystrophin
associated glycoprotein, DAG). The DAG complex gives structural stability to the muscle fiber,
linking dystrophin with the plasma membrane of muscle cells and the extracellular matrix [3].
The loss or reduction of sarcoglycans’ function results in the destabilization of the DAG com-
plex, and may be related to development of muscular dystrophy. The related impact on respira-
tory function and the presence of cardiomyopathy are associated with reduced life expectancy,
particularly in Duchenne muscular dystrophy (DMD) [4] where respiratory failure is a leading
cause of morbidity and mortality [5]. Sleep-related breathing disorders (SRBD) have also fre-
quently been observed in DMD and may affect disease prognosis [6,7].
Clinical presentation of LGMD is diverse but usually shows predominant proximal weak-
ness. Cardiac involvement, ranging from electrocardiographic (ECG) abnormalities to dilated
cardiomyopathy (DCM), has been reported in 17% to 50% of patients with sarcoglycanopathies
(SG) [8,9]. The involvement of striated muscles may also result in an impaired respiratory
muscle function (10). Patients with 2C and 2D LGMD seem to have a greater respiratory
impairment than other sarcoglycanopathies [10]. Long-term noninvasive ventilation (NIV)
has resulted in improved survival for patients with muscular dystrophy [11]. However, the evo-
lution of respiratory and heart function in muscular dystrophy patients, as well as their respec-
tive impact on prognosis, has been poorly described.
Cardiac and Respiratory Involvement, Prognosis and Long-Term Survival in LGMD2C and 2D
PLOSONE | DOI:10.1371/journal.pone.0153095 April 27, 2016 2 / 14
The aims of the study conducted in a group of 34 LGMD 2C and 2D patients followed-up
for a maximum of 10 years were to describe the long-term follow-up of their cardiac and respi-
ratory function, to assess the eventual association between cardiac and respiratory impairment
and to establish long-term survival rate and predictive factors of cardiac and respiratory events
and of mortality in 2C and 2D LGMD.
Methods
Study design
We retrospectively reviewed the charts of all LGMD 2C and 2D followed at the Home Mechan-
ical Ventilation Unit of the Raymond Poincare University Hospital, a tertiary neuromuscular
center (Garches, France). Neuromuscular patients are seen in the unit at least yearly to monitor
their respiratory function.
We included all adult patients (>18 years) with genetically confirmed 2C or 2D LGMD.
These patients were addressed to the unit for assessment and management of respiratory func-
tion because of a suspected respiratory impairment. For each patient, we collected echocardio-
graphic results, respiratory function, sleep recording and outcome data. The initial visit in the
unit that includes both a respiratory and an echocardiographic assessment was considered the
baseline for the present study.
The study was performed in compliance with the ethical principles formulated in the decla-
ration of Helsinki and was approved by the comité de protection des personnes and the commis-
sion nationale de l'informatique et des libertés. The study was registered in ClinicalTrials. gov
(identifier: NCT02501083).
Genetic tests
SGCA and SGCC gene analyses for mutation identification were performed using direct
sequencing or multiplex quantitative fluorescent PCR (QF-PCR) of genomic DNA extracted
from whole blood using standard procedures.
Cardiac function
Echocardiography was performed with a Siemens CV70 device. Echocardiographic measure-
ments were made and interpreted according to the guidelines published by the American Soci-
ety of Echocardiography [12] by two experienced cardiologists (AF and ON). Patients with
LVEF<50% were considered to have left ventricular systolic dysfunction [13].
Respiratory Function and Nocturnal Sleep Recording
A pulmonary function testing system (Vmax 229, SensorMedics, Yorba Linda, California) was
used to make the spirometric-static measurements of vital capacity (VC), according to standard
guidelines [14]. For the measurement of maximal inspiratory pressure (MIP) at the residual
volume and maximal expiratory pressure (MEP) at total lung capacity, patients breathed into a
mouthpiece connected to a manometer. The maneuvers were repeated at least three times or
until two identical readings were obtained. For each maneuver, the best result was kept for the
study [15].
From the routinely performed daytime arterial or arterialized capillary blood gases, we
recorded diurnal carbon dioxide tension (pCO2) and bicarbonate. The results of nocturnal
oximetry, performed with a Covidien Nellcor oximeter were also collected (percentage of sleep
time with oxygen saturation SaO2<90%). We also recorded apnea hypopnea index (AHI)
from the first available polysomnography after the initial visit.
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Outcomes
We considered respiratory events, cardiac events and mortality as outcomes of interest for the
present analysis. Cardiac events were defined as the onset of either acute heart failure syndrome
(AHF), cardiac arrhythmia (atrial fibrillation, atrial flutter, ventricular tachycardia, and ven-
tricular fibrillation), significant conduction block (atrioventricular block type II or III, sino
atrial block type III) or ischemic stroke. The diagnosis of arrhythmia or conduction block was
confirmed by a cardiologist (AF or ON) reviewing the original documents.
Respiratory events were defined as the onset of pulmonary sepsis, acute respiratory failure
(ARF), atelectasis or pneumothorax.
For each outcome, only the first occurrence was considered. As a part of the routine follow-
up, neuromuscular disease patients are contacted at least annually to plan their follow-up visit
in our unit and to record vital status. During each visit, details of intercurrent hospitalizations
are systematically collected in the medical charts.
Statistical Analysis
Continuous variables were described by median ± interquartile range (IQR) and compared by
Wilcoxon Rank Sum test; dichotomous or categorical variables were described by number of
subjects and percentage and compared by Fisher’s exact test. The associations between respira-
tory and cardiac continuous parameters were explored by the nonparametric Spearman’s cor-
relation coefficient. Survival curves were estimated by the Kaplan-Meier method and then
compared by the log-rank test; univariable Cox models allowed to estimate the strength of
association based on the hazard ratio (HR). Statistical analysis was performed using R1
(http://www.r-project.org/).
Results
A total of 34 patients were included in our study: 21 (62%) had LGMD 2C and 13 (38%) had
LGMD 2D.
Age ranged from 20 years to 48 years with a median age of 30 years; median age of ambula-
tion loss was 15 years [14–21]. Baseline characteristics of the population are detailed in Table 1
(percentages were calculated separately in each group of patients).
SGCA and SGCC Gene Analysis
Two SGCC mutations were found. All patients with LGMD 2C had the homozygous mutation
Del525T in exon 6 except 2 patients who were carrying the homozygous mutation C283Y in
exon 8. The following mutations were found in LGMD 2D patients (gene SGCA): homozygous
R77C (4/14 patients, homozygous IVS1+3A> T (3/14 patients), R77C/K252Vfs8 (2/14
patients), R98H and V75A (2 patients/14), R77C+R74W (1 patient), R98H/IVS7-1G> T (1
patient).
Respiratory and Cardiac Function
Included patients had severe restrictive respiratory defects with a median [IQR] pulmonary
vital capacity (VC) of 31% [20–40] of predicted capacity. About 35% of the patients were on
home mechanical ventilation at the initial visit, mostly non-invasive (3 patients ventilated by
tracheostomy) (Table 1). A total of 13 out of 34 patients (38%) had left ventricular systolic dys-
function. LV dysfunction was mild (LVEF 40–50%) in 20.5% of patients, moderate (LVEF 30–
40%) in 8.8% and severe (LVEF<30%) in 8.8% of patients.
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When comparing patients with 2C and 2D LGMD, we observed no differences in respira-
tory function, whereas LGMD 2C patients showed more severe cardiac impairment (Table 1).
We found no significant association between respiratory and cardiac function at baseline
(p = 0.76 for the correlation between LVEF and VC).
A follow-up evaluation of LVEF was available for 18 patients after a median time of 77.8
months [IQR 49.2–88.7] months and showed a stable cardiac function over time. On the other
hand, respiratory function deteriorated during the 65.6 months [IQR 46.3–80.7] follow-up for
the 24 patients for which this information was available (Fig 1).
Twelve patients started HMV during their follow-up. At the end of the follow-up period, 24
patients (70%) were treated by HMV.
Table 1. Characteristics of the study population.
All LGMD 2D LGMD 2C P value
N 34 (100%) 13 (38.23%) 21 (61.77%)
Age (y) 30 [24; 38] 30 [25; 40] 27 [23; 37] 0.27
Male gender 20 (58.82%) 7 (53.85%) 13 (61.9%) 0.73
Age of ambulation loss (y) 15 [14; 21] 15 [14; 20.25] 15 [13; 21] 0.50
Pre-albumin (mg/dl) 0.24 [0.22; 0.33] 0.23 [0.22; 0.33] 0.25 [0.22; 0.32] 0.95
Respiratory function
VC (ml) 1140 [850; 1820] 1110 [530; 1500] 1175 [850; 1842] 0.33
VC (% pred) 31 [20; 39.75] 28 [19; 40] 33 [23; 39] 0.62
MIP (cmH2O) 31 [20.25; 39.75] 27 [11.25; 41.5] 33.5 [21.75; 38.25] 0.81
MEP (cmH2O) 30.5 [20.25; 35.75] 30.5 [23.75; 42.75] 30.5 [19.75; 35.25] 0.77
HMV 12 (35.29%) 5 (38.46%) 7 (33.33%) 1.00
Tracheostomy 3 (8.82%) 1 (7.69%) 2 (9.52%) 1.00
Diurnal pCO2 (kPa) 5.75 [5.42; 6.27] 5.7 [5.34; 6.05] 5.75 [5.57; 6.34] 0.36
Diurnal bicarbonates (mmol/l) 26.9 [25.4; 28.6] 26.7 [25.75; 28.45] 26.9 [25.4; 28.9] 0.96
AHI 7.7 [3.5; 19] 11.4 [6.2; 15.2] 4 [4; 19] 0.88
Nocturnal SatO2<90%—(% of the recording time) 1 [0; 1.5] 1 [0; 1] 1 [1; 1.87] 0.26
Cardiac function
LVEF (%) 55 [45; 64] 63 [57; 65] 48.5 [42.25; 58.5] 0.014
LVEDD (mm) 41.5 [37.25; 47.25] 39[38; 42] 44 [37; 49] 0.37
ACE inhibitors 13(38.24%) 2 (15.38%) 11 (52.38%) 0.06
Beta-blockers 10 (29.41%) 0 (0%) 10 (47.62%)
Sinus rhythm 34 (100%) 13 (100%) 21 (100%)
HR (bpm) 88.5 [80; 93.75] 92 [86.75; 94.5] 86 [76.25; 90.5] 0.13
Values are expressed ad median [interquartile range] or number (proportion).
VC: pulmonary vital capacity (% pred: percent of the predicted value)
MIP: maximal inspiratory pressure
MEP: maximal expiratory pressure
HMV: home mechanical ventilation
AHI: apnea hypopnea index
SatO2: percentage of oxygen saturation
LVEF: left ventricular ejection fraction
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Apnea Hypopnea Index
AHI was available only in 8 patients raging from 1 to 38 without any differences in the 2 groups
(p 0.88) (Table 1).
Long-term Outcomes and Predictors of Outcomes
Over a median follow-up of 6 years [IQR 41–96 months], we observed 13 respiratory events
(38%), 5 cardiac events (15%) and 7 deaths (21%). A total of 16 patients (47%) experienced at
least one of the 3 outcomes. The cumulative incidence of these outcomes during the follow up
time is represented in Fig 2.
The Fig 3 shows the global survival curves of patients with LGM2D and 2C over time.
Among respiratory events, 13 patients (38%) experienced acute respiratory failure (ARF), 7
(20%) patients had pulmonary sepsis, 1 patient had atelectasis and 1 patient had
pneumothorax.
Among cardiac events, 4 patients (12%) had acute heart failure (AHF) and 2 patients had
ischemic stroke (6%). Respiratory parameters at baseline were significantly associated with the
occurrence of respiratory events, with an OR of 0.93 (95% CI 0.87–0.99, p 0.008) for VC and
an OR 6.80 (95% CI 1.4–32.4, p 0.025) for the need for HMV (Table 2). MIP and MEP were
significantly associated with the occurrence of respiratory events with an OR of 0.93 (95%CI
0.87–1.00) for MIP and an OR 0.94 (95% CI 0.88–1.01) for MEP (Table 2).
The level of diurnal pCO2 tended to be associated with the occurrence of respiratory events
with an OR of 2.91 (95%CI 0.85–9.91). Diurnal bicarbonate level tended to be significantly
associated with the occurrence of respiratory events with an OR of 1.41 (95% CI 0.99–2.00).
Fig 1. Evolution of respiratory vital capacity (VC) and left ventricular ejection fraction (LVEF) over the
follow-up time. Follow up time was 65.6 [IQR 46.28; 80.68] months between VC1 and VC2 and 80.8 months
[IQR 53.1; 89] months between LVEF1 and LVEF2. VC: pulmonary vital capacity. LVEF: left ventricular
ejection fraction.
doi:10.1371/journal.pone.0153095.g001
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Fig 2. Cumulative incidence of the studied outcomes.
doi:10.1371/journal.pone.0153095.g002
Fig 3. Global survival of the study population.
doi:10.1371/journal.pone.0153095.g003
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On the other hand, cardiac events were associated with LVEF at baseline (p 0.004), but not
with respiratory parameters, excepted for the presence of tracheostomy (Table 3). Baseline HR
did not predict the occurrence of cardiac events (Table 3).
Cardiac function at baseline with impaired LVEF (p 0.001) and left ventricular end diastolic
diameter (LVEDD) were associated with mortality (p 0.05). No association was found between
respiratory impairment and survival (Table 4 and Fig 4). We observed no differences in mortal-
ity between the types of sarcoglycanopathy.
Discussion
We describe the first available data on the association between cardiac and respiratory
impairment in a cohort of 34 patients with 2C and 2D LGMD, followed in our reference center
for a period of up to 10 years. We also described the evolution of their cardiac and respiratory
function over time as well as the association between function reduction and disease prognosis.
Heart
In this study, left ventricular function was altered in 38% of patients. Patients with mutations
in gamma sarcoglycan had more severe cardiac dysfunction than patients with alpha sarcogly-
can mutations. This can be partially explained by the consequences of the related mutations
Table 2. Factors associated with respiratory events.
Factors No respiratory events (N = 21) Respiratory events(N = 13) P value
LGM 2D 33.33% 46.15% 0.49
Age (y) 25 [23; 38] 31 [30; 38] 0.17
Male gender 61.9% 53.85% 0.73
Age of ambulation loss (y) 14.5 [13.25; 20.5] 16 [14; 20.5] 0.83
Pre albumin (mg/dl) 0.24 [0.22; 0.31] 0.3 [0.22; 0.33] 0.50
Baseline VC (ml) 1630 [1125; 1985] 850 [590; 1010] 0.004
Baseline VC (%pred) 35 [26; 43] 20 [16; 28] 0.008
MIP (cmH2O) 37 [23; 40.5] 22 [14; 29.5] 0.047
MEP (cmH2O) 33 [23.5; 37.5] 25 [15; 30.5] 0.055
Diurnal pCO2 (kPa) 5.6 [4.97; 5.97] 6.2 [5.65;6.32] 0.08
Diurnal bicarbonate (mmol/l) 26.3 [25; 28.1] 28.3 [25.9; 29.6] 0.069
Nocturnal SatO2<90% (%) 1 [0; 1.25] 1 [0.25; 1.75] 0.77
HMV 19.05% 61.54% 0.025
Tracheostomy 4.76% 15.38% 0.54
LVEF (%) 55 [45; 64.25] 55[45; 64] 0.88
LVEDD (mm) 43 [38.25; 48] 40.5 [37; 45] 0.64
Values are expressed ad median [interquartile range] or number (proportion).
VC: pulmonary vital capacity
MIP: maximal inspiratory pressure
MEP: maximal expiratory pressure
SatO2: percentage of oxygen saturation
HMV: home mechanical ventilation
HR: heart rate
LVEF: left ventricular ejection fraction
LVEDD: left ventricular end diastolic diameter
doi:10.1371/journal.pone.0153095.t002
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[16]. SGCA are missense that still leads to protein synthesis, thus maintaining some sarcogly-
can function, whereas mutations in SGCC are usually truncation without protein production
[17]. Our results confirm the preliminary results of a previous study by our team [18], which
included 19 patients with alpha and gamma sarcoglycanopathies. Left ventricular systolic dys-
function was observed in 30% of patients. Heart involvement has been previously reported in a
few series of patients with sarcoglycanopathies [9,10,19]. A high prevalence of cardiac
impairment (29% and 67%) has been reported in patients with respectively LGMD 2I and
LGMD 2E, without correlation with age or skeletal muscle strength [20]. In a second study, car-
diac involvement was reported in 63% of patients with LGMD type 2E [21]. Preclinical cardio-
myopathy was present in 44% of patients with sarcoglycanopathies in an Italian study, where
2/20 patients (10%) had an initial dilated cardiomyopathy [10]. In a recent Dutch study, 17%
out of the 24 assessed patients with sarcoglycanopathy showed dilated cardiomyopathy [8]. In
our study, we observed a higher prevalence than the previously published studies. This may be
related to the differences in disease duration as suggested from the differences in the median
ages: 23 years for the Italian study, 25 years in the Dutch study and 30 years in our population.
Acute ischemic stroke was found in 6% of our patients and was related to dilated cardiomyopa-
thy. Little is known about this complication in LGMD [22]. These results highlight the need for
potential preventive treatment in LGMD patients with severe heart failure.
Table 3. Factors associated with cardiac events.
Factors No cardiac events (n = 29) Cardiac events (n = 5) P value
LGM 2D 44.83% 0%
Age (y) 30 [24; 39] 30 [23; 31] 0.53
Male gender (%) 41.38% 40% 1.00
Age of ambulation loss (y) 15 [14; 19] 18.5 [12.75; 23] 1.00
Pre-albumin (mg/dl) 0.24 [0.22; 0.33] 0.32 [0.23; 0.33] 1.00
Baseline VC (%pred) 1210 [850; 1820] 980 [690; 1358] 0.51
MIP (cmH2O) 33.5 [20.25; 40] 29.5 [24.25; 31.75] 0.52
MEP (cmH2O) 30.5 [21.25; 35.75] 26.5 [17; 37.5] 0.85
Diurnal pCO2 (kPa) 5.85 [5.5; 6.29] 5.2 [4.41;5.82] 0.20
Diurnal bicarb (mmol/l) 26.9 [25.7; 28.6] 23.8 [21; 26.8] 0.19
Nocturnal SatO2<90% (%) 1[0; 1.37] 1[1; 5.5] 0.27
HMV 34.48% 40% 1.00
Tracheostomy 3.45% 40% 0.050
HR (bpm) 88 [80; 94] 89 [88.5; 90] 0.89
LVEF (%) 59 [48; 65] 30 [28; 40] 0.004
LVEF <55% (%) 42.86% 100% 0.04
LVEDD (mm) 40.5 [37; 45.75] 52.5 [48.25; 56.75] 0.15
Values are expressed ad median [interquartile range] or number (proportion).
VC: pulmonary vital capacity
MIP: maximal inspiratory pressure
MEP: maximal expiratory pressure
SatO2: percentage of oxygen saturation
HMV: home mechanical ventilation
HR: heart rate
LVEF: left ventricular ejection fraction
LVEDD: left ventricular end diastolic diameter
doi:10.1371/journal.pone.0153095.t003
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Pulmonary and Sleep
The involvement of striated muscles impairment may result in reduced respiratory muscle
function in patients with LGMD. Respiratory defects may be present early, particularly in
LGMD 2I [23,24]. In our study all patients had a severe restrictive respiratory failure at the
baseline visit, and 70% needed home mechanical ventilation at the end of the follow-up. This
prevalence is remarkably higher than what described in the study by Politano et al. [10], in
which a mild respiratory impairment was detected in 35% of patients and 12% showing severe
respiratory failure. In the study by Poppe et al. [25], 36% of patients with LGMD 2I showed
moderate respiratory impairment defined by a VC between 41% and 75%. Severe respiratory
defects, defined by VC between 19% and 40%, was seen only in 8% of the patient despite a simi-
lar age profile than our population.
Major differences between the Italian and present study were the median age of the studied
population, and the specificities of the recruitment centers: a cardiology department for the
Italian study and a respiratory center for neuromuscular diseases in our study.
In our population, we found no association between the severity of the respiratory dysfunc-
tion and presence of cardiac defects. Not surprisingly, our study found a significant association
Table 4. Factors associated with mortality.
Factors Alive Death P value
LGM 2D 44.44% 14.29% 0.21
Age (y) 30 [24; 37.5] 31 [26.5; 41.5] 0.46
Male gender 55.56% 71.43% 0.67
Age of ambulation loss (y) 14.5 [13.75; 18.25] 23 [14; 23] 0.45
Pre albumin (mg/dl) 0.24 [0.22; 0.33] 0.33 [0.27; 0.37] 0.37
Baseline VC (% pred) 31 [21; 39.5] 35 [18; 40] 0.98
Baseline VC (ml) 1210[850; 1760] 1025 [842; 1718] 0.77
MIP (cmH2O) 33.5[20.75; 40.25] 29.5[14.75; 35.25] 0.36
MEP (cmH2O) 30.5 [20.5; 36.25] 30 [22.25; 32.5] 0.84
Diurnal pCO2 (kPa) 5.85 [5.5; 6.3] 5.2 [4.7; 5.8] 0.11
Diurnal bicarbonates (mmol/l) 26.9 [25.8; 28.5] 25.6 [22.6; 28.6] 0.35
Nocturnal SatO2<90% (%) 1 [0; 1] 1.25 [1; 3.6] 0.15
AHI 7.7 [2.5; 17.1] 11.5 [7.75; 15.25] 0.87
HMV 33.33% 42.86% 0.68
Tracheostomy 3.7% 28.57% 0.10
HR(bpm) 89 [80; 94] 84 [80; 89] 0.37
LVEF (%) 60 [49.25; 65] 40 [29; 45] 0.001
LVEF<55% 38.46% 100% 0.007
LVEDD(mm) 40[37; 44.5] 50 [47; 55.5] 0.055
Values are expressed ad median [interquartile range] or number (proportion).
VC: pulmonary vital capacity
MIP: maximal inspiratory pressure
MEP: maximal expiratory pressure
SatO2: percentage of oxygen saturation
HMV: home mechanical ventilation
HR: heart rate
LVEF: left ventricular ejection fraction
LVEDD: left ventricular end diastolic diameter
doi:10.1371/journal.pone.0153095.t004
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between the level of MIP, the level of MEP and the occurrence of respiratory events in LGMD.
Indeed, MIP and MEP explore respiratory muscle strength. With expiratory muscle failure,
patients are at risk of respiratory sepsis and failure because of the impairment of cough and
respiratory airway clearance.
Neuromuscular diseases may be associated with ventilatory disturbances and sleep-related
breathing disorders (SRBD) [26]. SRBD may be present early in the natural history of patients
with DMD and occurred in 64% of patients in the study by Suresh et al. [6]. A moderate
decrease of VC in patients with LGMD has been reported by Gigliotti et al. [27] with a good
correlation between daytime pCO2 and VC. Moreover, functional pulmonary tests may predict
nocturnal hypoventilation [28,29]. In our study, we found few abnormal sleep recordings,
which may be explained by the use of nocturnal noninvasive ventilation in a subset of the pop-
ulation. Our study found, however, a trend to a significant association between diurnal pCO2
and respiratory events, as well as an association between VC and respiratory events. These
results may suggest that respiratory and sleep evaluation should be performed systematically in
LGDM. The ATS consensus statement recommends annual evaluation for sleep-disordered
breathing in patients with DMD starting from the time they become wheel chair bounded and/
or when clinically indicated [30]. This recommendation may be applied to 2C and 2D LGMD.
Prognosis and Mortality
Respiratory failure is a major cause of morbi-mortality in neuromuscular diseases [31] and was
the main cause of death in DMD a few decades ago (up to 73% of patients in the study by
Rideau et al., published in 1983) [4]. Identifying prognostic factors is essential in patients with
Fig 4. Mortality according to left ventricular function. Patients were divided in the two groups using the
median value of LVEF (55%) as a cut-off.
doi:10.1371/journal.pone.0153095.g004
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neuromuscular disorders. However, no data exists to date for prognostic factors in 2C and 2D
LGMD. A VC under 1000 ml, the presence of daytime hypercapnia and nocturnal hypoxemia
have been previously described as mortality predictors in patients with Duchenne muscular
dystrophy [32].
Left ventricular cardiac dysfunction has already been associated with mortality in 2I LGMD
(23, 24). In our cohort, cardiac impairment was significantly associated with mortality. A
LVEF<55% was associated with an increased mortality in 2C and 2D LGMD. On the other
hand, respiratory defects were associated with respiratory events but not with mortality. This
observation suggests that it could be possible to overcome acute respiratory failure episodes,
which occurred in a relevant proportion of our patients, and thus reducing respiratory related
mortality. This encouraging result could be explained by the efficacy of long-term respiratory
support technics, which have already been shown to improve survival in other neuromuscular
diseases [33,11,34,35]. Improved cardiology and respiratory management of neuromuscular
disease patients has been associated with prolonged survival in DMD patients [36,37]. Kohler
et al. [38] reported an 85% survival at 30 years in DMD patients. As a consequence of the
improved respiratory management, cardiac failure has become the main cause of mortality in
DMD. Bach et al. [39] reported 52% of cardiac mortality and 21% of respiratory mortality
among patients with DMD. In our study, global mortality rate was 21% with half for primary
cardiac causes, despite ACE inhibitors and beta-blocker regimens.
Limitations of the Study
Our study was mono-centric and retrospective and the results may be hampered by the limited
sample size and the recruitment specificities of our unit. Future multi-centric studies may be
helpful to better characterize the phenotype and prognosis of type 2C and 2D LGMD.
Conclusion
In our cohort of severely respiratory impaired LGMD 2C and 2D patients, we observed a 21%
mortality rate. Significant respiratory events occurred in 38% of patients over a median follow-
up of 6 years. Left ventricular dysfunction was observed in 38% of patients and was associated
with mortality. Both cardiac failure and respiratory impairment seem to have an important
prognostic impact on morbidity and mortality in LGMD 2C and 2D patients, but the evolution
of these two systems seems not to be correlated. These results warrant the need for a multidisci-
plinary follow-up of LGMD patients, including cardiologists and pulmonologists. Based on our
experience and on the presented data, we recommend a yearly respiratory function evaluation
including a sleep study, as well as cardiac defects screening in order to introduce treatment for
heart failure when LVEF declines.
Acknowledgments
To Henri LELEU, MD, PhD, Paris for the English relecture of the manuscript.
Author Contributions
Conceived and designed the experiments: AF AO DA. Performed the experiments: AF AO
ON. Analyzed the data: CC SC AF AO DA. Contributed reagents/materials/analysis tools: AF
AO RGC F. Leturcq HP AB TS PL F. Lofaso DO. Wrote the paper: AF AO RGC F. Leturcq KW
BC PL DA.
Cardiac and Respiratory Involvement, Prognosis and Long-Term Survival in LGMD2C and 2D
PLOSONE | DOI:10.1371/journal.pone.0153095 April 27, 2016 12 / 14
References
1. Noguchi S, McNally EM, Ben Othmane K, Hagiwara Y, Mizuno Y, Yoshida M, et al. Mutations in the
dystrophin-associated protein gamma-sarcoglycan in chromosome 13 muscular dystrophy. Science.
1995 Nov 3; 270(5237): 819–22. PMID: 7481775
2. Roberds SL, Leturcq F, Allamand V, Piccolo F, Jeanpierre M, Anderson RD, et al. Missense mutations
in the adhalin gene linked to autosomal recessive muscular dystrophy. Cell. 1994 Aug 26; 78(4):625–
33. PMID: 8069911
3. Sandonà D, Betto R. Sarcoglycanopathies: molecular pathogenesis and therapeutic prospects. Expert
Rev Mol Med. 2009 Sep 28; 11:e28. doi: 10.1017/S1462399409001203 PMID: 19781108
4. Rideau Y, Gatin G, Bach J, Gines G. Prolongation of life in Duchenne’s muscular dystrophy. Acta Neu-
rol (Napoli). 1983 Apr; 5(2):118–24.
5. Nagai T. Prognostic evaluation of congestive heart failure in patients with Duchenne muscular dystro-
phy—retrospective study using non-invasive cardiac function tests. Jpn Circ J. 1989 May; 53(5):406–
15. PMID: 2769928
6. Suresh S, Wales P, Dakin C, Harris MA, Cooper DG. Sleep-related breathing disorder in Duchenne
muscular dystrophy: disease spectrum in the paediatric population. J Paediatr Child Health. 2005 Sep-
Oct; 41(9–10):500–3. PMID: 16150067
7. Bourke SC, Gibson GJ. Sleep and breathing in neuromuscular disease. Eur Respir J. 2002 Jun; 19
(6):1194–201. PMID: 12108875
8. Schade vanWestrum SM, Dekker LR, de Voogt WG,Wilde AA, Ginjaar IB, et al. Cardiac involvement
in Dutch patients with sarcoglycanopathy: a cross-sectional cohort and follow-up study. Muscle Nerve.
2014 Dec; 50(6):909–13. doi: 10.1002/mus.24233 PMID: 24619517
9. Fanin M, Melacini P, Boito C, Pegoraro E, Angelini C. LGMD2E patients risk developing dilated cardio-
myopathy. Neuromuscul Disord 2003; 13:303–9. PMID: 12868499
10. Politano L, Nigro V, Passamano L, Petretta V, Comi LI, Papparella S,et al. Evaluation of cardiac and
respiratory involvement in sarcoglycanopathies. Neuromuscul Disord. 2001 Mar; 11(2):178–85. PMID:
11257475
11. Simonds AK, Muntoni F, Heather S, Fielding S. Impact of nasal ventilation on survival in hypercapnic
Duchenne muscular dystrophy. Thorax. 1998 Nov; 53(11):949–52. PMID: 10193393
12. Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL, et al.; ACC; AHA; ASE.
ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: summary arti-
cle. A report of the American College of Cardiology/American Heart Association Task Force on Practice
Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of
Echocardiography).J Am Soc Echocardiogr. 2003 Oct; 16(10):1091–110. PMID: 14566308
13. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, BöhmM, Dickstein K, et al.; ESC Committee for
Practice Guidelines.ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the
European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of
the ESC. Eur Heart J. 2012 Jul; 33(14):1787–847. doi: 10.1093/eurheartj/ehs104 PMID: 22611136
14. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirom-
etry. Eur Respir J 2005; 26(2):319–338. PMID: 16055882
15. American Thoracic Society; European Respiratory Society. ATS/ERS statement on respiratory muscle
testing. Am J Respir Crit Care Med 2002; 166:528–547.
16. Duggan DJ, Gorospe JR, Fanin M, Hoffman EP, Angelini C. Mutations in the sarcoglycan genes in
patients with myopathy. N Engl J Med. 1997 Feb 27; 336(9):618–24. PMID: 9032047
17. Trabelsi M, Kavian N, Daoud F, Commere V, Deburgrave N, Beugnet C, et al. Revised spectrum of
mutations in sarcoglycanopathies. Eur J HumGenet. 2008 Jul; 16(7):793–803. doi: 10.1038/ejhg.2008.
9 PMID: 18285821
18. Fayssoil A, Nardi O, Annane D, Orlikowski D. Left ventricular function in alpha-sarcoglycanopathy and
gamma-sarcoglycanopathy. Acta Neurol Belg. 2014 Dec; 114(4):257–9. doi: 10.1007/s13760-013-
0276-5 PMID: 24464767
19. Calvo F, Teijeira S, Fernandez JM, Teijeiro A, Fernandez-Hojas R, Fernandez-Lopez XA, et al. Evalua-
tion of heart involvement in gamma-sarcoglycanopathy (LGMD2C). A study of ten patients. Neuromus-
cul Disord. 2000 Dec; 10(8):560–6. PMID: 11053682
20. Sveen ML, Thune JJ, Køber L, Vissing J. Cardiac involvement in patients with limb-girdle muscular dys-
trophy type 2 and Becker muscular dystrophy. Arch Neurol. 2008 Sep; 65(9):1196–201. doi: 10.1001/
archneur.65.9.1196 PMID: 18779423
Cardiac and Respiratory Involvement, Prognosis and Long-Term Survival in LGMD2C and 2D
PLOSONE | DOI:10.1371/journal.pone.0153095 April 27, 2016 13 / 14
21. Semplicini C, Vissing J, Dahlqvist JR, Stojkovic T, Bello L, Witting N,et al. Clinical and genetic spectrum
in limb-girdle muscular dystrophy type 2E. Neurology. 2015 Apr 28; 84(17):1772–81. doi: 10.1212/
WNL.0000000000001519 PMID: 25862795
22. Chen CH, Tang SC, Su YN, Yang CC, Jeng JS. Cardioembolic stroke related to limb-girdle muscular
dystrophy 1B. BMC Res Notes. 2013 Jan 29; 6:32. doi: 10.1186/1756-0500-6-32 PMID: 23360689
23. Petri H, Sveen ML, Thune JJ, Vissing C, Dahlqvist JR, Witting N, et al. Progression of cardiac involve-
ment in patients with limb-girdle type 2 and Becker muscular dystrophies: a 9-year follow-up study. Int J
Cardiol. 2015 Mar 1; 182:403–11. doi: 10.1016/j.ijcard.2014.12.090 PMID: 25596466
24. Boito CA, Melacini P, Vianello A, Prandini P, Gavassini BF, Bagattin A, et al. Clinical and molecular
characterization of patients with limb-girdle muscular dystrophy type 2I. Arch Neurol. 2005 Dec; 62
(12):1894–9. PMID: 16344347
25. Poppe M, Bourke J, Eagle M, Frosk P, Wrogemann K, Greenberg C,et al. Cardiac and respiratory fail-
ure in limb-girdle muscular dystrophy 2I. Ann Neurol. 2004 Nov; 56(5):738–41. PMID: 15505776
26. Toussaint M, Steens M, Soudon P. Lung function accurately predicts hypercapnia in patients with
Duchenne muscular dystrophy. Chest. 2007 Feb; 131(2):368–75. PMID: 17296635
27. Gigliotti F, Pizzi A, Duranti R, Gorini M, Iandelli I, Scano G. Control of breathing in patients with limb gir-
dle dystrophy: a controlled study. Thorax. 1995 Sep; 50(9):962–8. PMID: 8539676
28. Ragette R, Mellies U, Schwake C, Voit T, Teschler H. Patterns and predictors of sleep disordered
breathing in primary myopathies. Thorax. 2002 Aug; 57(8):724–8. PMID: 12149535
29. Hukins CA, Hillman DR. Daytime predictors of sleep hypoventilation in Duchenne muscular dystrophy.
Am J Respir Crit Care Med. 2000 Jan; 161(1):166–70. PMID: 10619815
30. Finder JD, Birnkrant D, Carl J, Farber HJ, Gozal D, Iannaccone ST,et al.; American Thoracic Society.
Respiratory care of the patient with Duchennemuscular dystrophy: ATS consensus statement. Am J
Respir Crit Care Med. 2004 Aug 15; 170(4):456–65. PMID: 15302625
31. Perrin C, Unterborn JN, Ambrosio CD, Hill NS. Pulmonary complications of chronic neuromuscular dis-
eases and their management. Muscle Nerve. 2004 Jan; 29(1):5–27. PMID: 14694494
32. Phillips MF, Smith PE, Carroll N, Edwards RH, Calverley PM. Nocturnal oxygenation and prognosis in
Duchenne muscular dystrophy. Am J Respir Crit Care Med. 1999 Jul; 160(1):198–202. PMID:
10390400
33. Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K.Survival in Duchenne muscular
dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation.
Neuromuscul Disord. 2002 Dec; 12(10):926–9. PMID: 12467747
34. Oskoui M, Levy G, Garland CJ, Gray JM, O’Hagen J, De Vivo DC, Kaufmann P. The changing natural
history of spinal muscular atrophy type 1.Neurology. 2007 Nov 13; 69(20):1931–6. PMID: 17998484
35. Annane D, Orlikowski D, Chevret S. Nocturnal mechanical ventilation for chronic hypoventilation in
patients with neuromuscular and chest wall disorders. Cochrane Database Syst Rev. 2014 Dec 13; 12.
36. Calvert LD, McKeever TM, Kinnear WJ, Britton JR. Trends in survival frommuscular dystrophy in
England andWales and impact on respiratory services. Respir Med. 2006 Jun; 100(6):1058–63. PMID:
16257521
37. Passamano L, Taglia A, Palladino A, Viggiano E, D’Ambrosio P, Scutifero M,et al. Improvement of sur-
vival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients. Acta Myol. 2012 Oct; 31
(2):121–5. PMID: 23097603
38. Kohler M, Clarenbach CF, Bahler C, Brack T, Russi EW, Bloch KE. Disability and survival in Duchenne
muscular dystrophy. J Neurol Neurosurg Psychiatry. 2009 Mar; 80(3):320–5. doi: 10.1136/jnnp.2007.
141721 PMID: 18713792
39. Bach JR, Martinez D. Duchennemuscular dystrophy: continuous noninvasive ventilator support pro-
longs survival. Respir Care. 2011 Jun; 56(6):744–50. doi: 10.4187/respcare.00831 PMID: 21333078
Cardiac and Respiratory Involvement, Prognosis and Long-Term Survival in LGMD2C and 2D
PLOSONE | DOI:10.1371/journal.pone.0153095 April 27, 2016 14 / 14
